Cover Image
Market Research Report

Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016

Published by Global Markets Direct Product code 410978
Published Content info 54 Pages
Immediate Delivery Available
Price
Back to Top
Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016
Published: December 30, 2016 Content info: 54 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016, provides an overview of the Wilms' Tumor (Nephroblastoma) (Oncology) pipeline landscape.

Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms' tumor is a rare kidney cancer that primarily affects children.Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC8891IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wilms' Tumor (Nephroblastoma) Overview
  • Therapeutics Development
    • Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview
    • Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis
  • Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies
  • Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes
  • Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Wilms' Tumor (Nephroblastoma) - Products under Development by Companies
  • Wilms' Tumor (Nephroblastoma) - Products under Investigation by Universities/Institutes
  • Wilms' Tumor (Nephroblastoma) - Companies Involved in Therapeutics Development
    • Exelixis Inc
    • NanoSmart Pharmaceuticals Inc
    • Recombio SL
    • Selvita SA
  • Wilms' Tumor (Nephroblastoma) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Wilms' Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • racotumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-12034 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Wilms' Tumor (Nephroblastoma) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016
  • Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by Exelixis Inc, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by Recombio SL, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by Selvita SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016
  • Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top